Press Releases Johnson & Johnson Buenos Aires S.E.

Equities

JNJD

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 23:00:00 23/06/2024 BST			5-day change	1st Jan Change
10.2 ^USD	+1.49%		+2.51%	0.00%

06-24	US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	RE
06-24	J&J: 50M pupils helped through 'Sight for Kids' program	CF

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	06-25	AQ
Johnson & Johnson completes acquisition of Proteologix, Inc.	06-24	AQ
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	06-21	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	06-21	AQ
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	06-20	PR
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	06-20	BU
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	06-20	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	06-18	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	06-17	BU
J&J commits five-year investment in Italian medicine manufacturing	06-17	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	06-17	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	06-17	AQ
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	06-15	PR
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	06-14	PU
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	06-14	PU
That's Stentertainment	06-13	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Press Release	06-12	PU
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy	06-12	BU
Johnson & Johnson agrees to pay $700M to settle talcum lawsuit with dozens of states	06-12	AQ
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Transcript	06-11	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm